Evive Biotech and Acrotech Biopharma receive FDA approval of Ryzneuta

Evonik launches GMP-quality plant-based squalene

PhytoSquene now available for clinical and commercial use

Pfizer and BioNTech announce data for mRNA-based vaccine program for influenza and COVID-19

The companies plan to start a pivotal Phase 3 trial in the coming months

USFDA accepts for review AstraZeneca’s supplemental biologics license application for self-administration of FluMist Quadrivalent

The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer

Ichnos Sciences inks agreement with Astria Therapeutics for OX40 antagonist monoclonal antibody portfolio

Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications

Sun Pharma gets USFDA filing acceptance of new drug application for Deuruxolitinib

The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials

Thermo Fisher Scientific expands St. Louis manufacturing for complex biologic treatments

Increased capability to produce medicines for challenging diseases including cancer

Nobel prize 2023 for medicine awarded to Katalin Karikó, Drew Weissman for research on mRNA vaccines to fight Covid-19

The discoveries by the two Nobel Laureates were critical for developing effective mRNA vaccines against COVID-19

Biocon Biologics completes integration of Viatris Biosimilars’ business in North America

Biocon Biologics recently acquired the global biosimilars business of its long-term partner Viatris

BioNTech to lead $2 billion mRNA-based oncology therapy market despite challenges, says GlobalData

BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials